India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Cryptocurrency exchange WazirX is introducing AI-powered trading tools, advanced trading products and customer experience upgrades followin...

The Unique Identification Authority of India (UIDAI) is making email address updates via the Aadhaar mobile app free for six months, from J...

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...

PhonePe clarifies inactivity fees apply solely to its prepaid wallet, not linked bank accounts or UPI transactions. Users receiving notific...

Phonographic Performance (PPL India), representing over 500 music labels, has officially received registration as a copyright society under...

In a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step fo...

PhonePe is now charging a Rs 100 quarterly fee for inactive wallets. This fee applies if users have not made any financial transactions thr...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...

WazirX Futures brings direct INR access, the lowest fees in the domestic market, and built-in risk guardrails to a segment that has quietly...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...